Covered recipient · General Payments record
DAVID R SUTTON
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$43,402.86
116 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,100.00 | 50 |
| Food and Beverage | $1,600.86 | 65 |
| Travel and Lodging | $702.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $28,043.84 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,796.20 | 16 |
| Zealand Pharma US, Inc. | $2,518.52 | 7 |
| AbbVie Inc. | $911.72 | 2 |
| Ultragenyx Pharmaceutical Inc. | $279.60 | 2 |
| Abbott Laboratories | $204.54 | 12 |
| Amgen Inc. | $97.77 | 7 |
| Horizon Therapeutics plc | $91.65 | 4 |
| Radius Health, Inc. | $86.20 | 5 |
| Xeris Pharmaceuticals, Inc. | $75.41 | 4 |
| Medtronic, Inc. | $65.00 | 3 |
| IBSA Pharma Inc. | $62.76 | 4 |
| Insulet Corporation | $47.63 | 3 |
| AstraZeneca Pharmaceuticals LP | $46.08 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.87 | 1 |
| Mannkind Corporation | $15.28 | 1 |
| LifeScan, Inc. | $14.57 | 1 |
| Tandem Diabetes Care, Inc. | $14.38 | 1 |
| Merck Sharp & Dohme Corporation | $12.84 | 1 |
Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID R SUTTON
NPI 1447252523 · CMS profile ID 337751
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
JACKSONVILLE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID R SUTTON, NPI 1447252523, CMS profile ID 337751. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAVID R SUTTON, NPI 1447252523, CMS profile ID 337751. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAVID R SUTTON, NPI 1447252523, CMS profile ID 337751, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
116 matching records · $43,402.86 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–116 of 116.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $800.00 | 03/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937106681 | CMS |
| Lilly USA, LLC | $800.00 | 03/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937110973 | CMS |
| Zealand Pharma US, Inc. | $800.00 | 02/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 800230623 | CMS |
| Lilly USA, LLC | $800.00 | 02/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937110381 | CMS |
| Lilly USA, LLC | $800.00 | 02/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937111297 | CMS |
| Lilly USA, LLC | $800.00 | 02/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937110773 | CMS |
| Lilly USA, LLC | $400.00 | 02/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937110971 | CMS |
| Lilly USA, LLC | $800.00 | 02/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937120551 | CMS |
| Lilly USA, LLC | $400.00 | 02/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937110377 | CMS |
| Zealand Pharma US, Inc. | $1,600.00 | 02/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 800230621 | CMS |
| Lilly USA, LLC | $800.00 | 02/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937109707 | CMS |
| Lilly USA, LLC | $800.00 | 01/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937120547 | CMS |
| Lilly USA, LLC | $400.00 | 01/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937107043 | CMS |
| Lilly USA, LLC | $800.00 | 01/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937110767 | CMS |
| Lilly USA, LLC | $800.00 | 01/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937111281 | CMS |
| Lilly USA, LLC | $800.00 | 01/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937111293 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $317,408.78 | 36 |
| PY2024 | Recipient | $4,329.00 | 1 |
| PY2024 | Principal investigator | $434,126.85 | 62 |
| PY2023 | Principal investigator | $542,750.08 | 214 |
| PY2022 | Principal investigator | $330,800.55 | 84 |
| PY2021 | Principal investigator | $282,569.88 | 23 |
| PY2020 | Principal investigator | $269,596.66 | 12 |
| PY2019 | Principal investigator | $167,008.98 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776561 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,500.00 | 11/25/2025 | Non-covered Recipient Entity Ecir Parent Llc | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190305035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 11/19/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 11/19/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776565 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 11/18/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998741 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $333.29 | 11/18/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220815926 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 10/01/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/01/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220776557 |
| Principal investigator 1 | Eli Lilly and Company | $97,494.00 | 08/05/2025 | Non-covered Recipient Entity NORTHEAST RESEARCH INSTITUTE | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187886062 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,335.42 | 06/20/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510433 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 06/20/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510456 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,406.25 | 06/20/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510459 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 06/20/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510464 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $360.00 | 06/04/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510485 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $720.00 | 06/04/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510488 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $650.00 | 05/28/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510448 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $217.50 | 05/21/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510480 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $45.00 | 05/07/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510441 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $550.00 | 05/07/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510492 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,600.00 | 05/01/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510445 |
| Principal investigator 1 | Eli Lilly and Company | $9,887.98 | 04/23/2025 | Non-covered Recipient Entity NORTHEAST RESEARCH INSTITUTE | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187886904 |
| Principal investigator 1 | Medtronic, Inc. | $3,500.00 | 04/10/2025 | Non-covered Recipient Entity East Coast Institute For Research Llc | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192323651 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,700.00 | 04/09/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510469 |
| Principal investigator 1 | Medtronic, Inc. | $500.00 | 03/13/2025 | Non-covered Recipient Entity East Coast Institute For Research Llc | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192323647 |
| Principal investigator 1 | Medtronic, Inc. | $375.00 | 03/13/2025 | Non-covered Recipient Entity East Coast Institute For Research Llc | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192323649 |
| Principal investigator 1 | Eli Lilly and Company | $946.30 | 02/25/2025 | Non-covered Recipient Entity NORTHEAST RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187886902 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,929.79 | 02/21/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215510426 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,195.00 | 02/11/2025 | Non-covered Recipient Entity EAST COAST INSTITUTE FOR RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190300175 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $547.65 | 01/15/2025 | Non-covered Recipient Entity EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190303699 |
| Principal investigator 1 | Eli Lilly and Company | $112,014.90 | 01/13/2025 | Non-covered Recipient Entity NORTHEAST RESEARCH INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187884836 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,065.50 | 01/07/2025 | Non-covered Recipient Entity EAST COAST INSTITUTE FOR RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190300223 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,047.41 | 01/07/2025 | Non-covered Recipient Entity EAST COAST INSTITUTE FOR RESEARCH, LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190307127 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $591.40 | 01/06/2025 | Non-covered Recipient Entity East Coast Institute for Research, LLC | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1215510515 |